Related Experiment Video
Updated: Jun 19, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
REDUCTION OF ARTERIAL BLOOD PRESSURE OF HYPERTENSIVE PATIENTS AND ANIMALS WITH EXTRACTS OF KIDNEYS
I H Page1, O M Helmer, K G Kohlstaedt
1Lilly Laboratory for Clinical Research, Indianapolis City Hospital, Indianapolis.
The Journal of Experimental Medicine
|October 30, 2009
Summary
Kidney extracts effectively lower blood pressure in patients with essential and malignant hypertension, as well as in hypertensive animals. This novel hypertension treatment shows promise but requires further research.
Area of Science:
- Nephrology
- Pharmacology
- Cardiovascular Medicine
Background:
- Hypertension, including essential and malignant forms, poses significant health risks.
- Current treatments for hypertension have limitations, necessitating the exploration of novel therapeutic approaches.
Purpose of the Study:
- To investigate the efficacy of kidney extracts in lowering arterial blood pressure in hypertensive patients and animal models.
- To evaluate the safety and optimal dosage of kidney extract treatment for hypertension.
Main Methods:
- Preparation of kidney extracts using various chemical procedures.
- Administration of extracts to hypertensive dogs, rats, and human patients.
- Monitoring of blood pressure, blood urea nitrogen, and clinical signs of toxicity.
Main Results:
- Kidney extracts significantly lowered arterial blood pressure in patients with essential and malignant hypertension, as well as in hypertensive animals.
- Successful reduction of blood pressure to normal levels was achieved in 60 hypertensive dogs and hypertensive rats.
- While generally safe when dosage is managed, rapid blood pressure reduction in animals could lead to a fatal shock syndrome. Three out of five malignant hypertension patients showed significant clinical improvement.
Conclusions:
- Kidney extracts demonstrate therapeutic potential in managing hypertension.
- The treatment is still in the experimental stage, requiring further investigation to determine optimal protocols and long-term efficacy.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:16Antihypertensive Drugs: Action of Diuretics
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:18Hypertension and Regulation of Blood Pressure
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...